Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Robert Wise (Baltimore, United States of America), Robert Wise, Andy Fowler, Norbert Metzdorf, Helen Dewberry, Achim Mueller, Peter Kowey. Safety of tiotropium in patients with cardiac events in the TIOSPIR™ trial. Eur Respir J 2015; 46: Suppl. 59, 985

Member's Comments

No comment yet.

Related content which might interest you: Safety of tiotropium in patients with cardiac events in the UPLIFT® trial Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Cardiac events among patients with CV comorbidities: Pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Long-acting bronchodilators (LABDs) and major adverse cardiac events (MACE) in patients with COPD: A pooled analysis of 12 randomised trials Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Safety of once-daily glycopyrronium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Cardio- and cerebrovascular safety of QVA149 in patients with moderate-to-severe COPD: A pooled analysis Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013 QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Prognostic factors of mortality and cardiovascular outcomes in the tiotropium safety and performance in respimat (TIOSPIR) trial Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Evaluating cardiac safety of tiotropium in patients with COPD: Combined analysis of Holter-ECG data from four trials Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Continuous indacaterol treatment improves autonomic cardiac regulation in COPD patients Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015 One-year mortality associated with COPD treatment: A comparison of tiotropium and long-acting beta-2-agonists Source: International Congress 2014 – Prevalence of COPD and mortality from COPD Year: 2014